References
1. Collaborators GBDS. Global, regional, and national burden of stroke
and its risk factors, 1990-2019: a systematic analysis for the Global
Burden of Disease Study 2019. Lancet Neurol. 2021;20:795-820.
2. Ma Q, Li R, Wang L, et al. Temporal trend and attributable risk
factors of stroke burden in China, 1990-2019: an analysis for the Global
Burden of Disease Study 2019. Lancet Public Health. 2021;6:e897-e906.
3. Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano
RP. Acute coronary syndromes. Lancet. 2022;399:1347-58.
4. Xian Y, Xu H, Matsouaka R, et al. Analysis of Prescriptions for Dual
Antiplatelet Therapy After Acute Ischemic Stroke. JAMA Netw Open.
2022;5:e2224157.
5. Simonte G, Guglielmini G, Falcinelli E, et al. High-on-treatment
platelet reactivity predicts adverse outcome after carotid artery
stenting: A prospective study. Thromb Res. 2023;222:117-23.
6. Shah J, Liu S, Yu W. Contemporary antiplatelet therapy for secondary
stroke prevention: a narrative review of current literature and
guidelines. Stroke Vasc Neurol. 2022;7:406-14.
7. Khan H, Kanny O, Syed MH, Qadura M. Aspirin Resistance in Vascular
Disease: A Review Highlighting the Critical Need for Improved
Point-of-Care Testing and Personalized Therapy. Int J Mol Sci. 2022;23.
8. Patel S, Arya V, Saraf A, Bhargava M, Agrawal CS. Aspirin and
Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its
Associations with Gene Polymorphisms: A Pilot Study. Ann Indian Acad
Neurol. 2019;22:147-52.
9. Ross S, Krebs K, Pare G, Milani L. Pharmacogenomics in Stroke and
Cardiovascular Disease: State of the Art. Stroke. 2023;54:270-8.
10. Montinari MR, Minelli S, De Caterina R. The first 3500 years of
aspirin history from its roots - A concise summary. Vascul Pharmacol.
2019;113:1-8.
11. Li XQ, Ma N, Li XG, et al. Association of PON1, P2Y12 and COX1 with
Recurrent Ischemic Events in Patients with Extracranial or Intracranial
Stenting. PLoS One. 2016;11:e0148891.
12. Zhao Z, Li X, Sun S, et al. Impact of genetic polymorphisms related
to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome
in Chinese patients with symptomatic extracranial or intracranial
stenosis. Eur J Clin Pharmacol. 2016;72:1195-204.
13. Pereira NL, Rihal CS, So DYF, et al. Clopidogrel Pharmacogenetics.
Circ Cardiovasc Interv. 2019;12:e007811.
14. Saiz-Rodriguez M, Belmonte C, Caniego JL, et al. Influence of CYP450
Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel
Response in Patients Subjected to a Percutaneous Neurointervention. Clin
Ther. 2019;41:1199-212 e2.
15. Pan Y, Elm JJ, Li H, et al. Outcomes Associated With
Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A
Pooled Analysis of Clopidogrel in High-Risk Patients With Acute
Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented
Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA
Neurol. 2019;76:1466-73.
16. Brown T, Gonzales N. Optimizing Choice of Dual Antiplatelet Therapy
in CYP2C19 Loss-of-Function Carriers. Neurology. 2023;100:223-4.
17. Yip VL, Pirmohamed M. Expanding role of pharmacogenomics in the
management of cardiovascular disorders. Am J Cardiovasc Drugs.
2013;13:151-62.
18. Jackson SP. Arterial thrombosis–insidious, unpredictable and
deadly. Nat Med. 2011;17:1423-36.
19. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin
alpha 2 beta 1 activity on human platelets. Blood. 1993;82:2693-703.
20. Deckmyn H, Chew SL, Vermylen J. Lack of platelet response to
collagen associated with an autoantibody against glycoprotein Ia: a
novel cause of acquired qualitative platelet dysfunction. Thromb
Haemost. 1990;64:74-9.
21. Huang XY, Fu WJ, Mei ZZ, et al. Association between platelet
glycoprotein Ia C807T gene polymorphism and ischemic stroke: a
meta-analysis in a separate ethnic group. Cell Mol Biol
(Noisy-le-grand). 2017;63:111-5.
22. Liu H, Wang Y, Zheng J, et al. Platelet glycoprotein gene Ia C807T,
HPA-3, and Ibalpha VNTR polymorphisms are associated with increased
ischemic stroke risk: Evidence from a comprehensive meta-analysis. Int J
Stroke. 2017;12:46-70.
23. de Oliveira MH, Andre C, Spector N, Luiz RR, de Castro Souza G,
Gadelha T. 807C/T polymorphism in the platelet glycoprotein Ia gene in
young patients with ischemic stroke of undetermined etiology. Blood
Coagul Fibrinolysis. 2007;18:599-602.
24. Nikolopoulos GK, Tsantes AE, Bagos PG, Travlou A, Vaiopoulos G.
Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a
meta-analysis. Thromb Res. 2007;119:501-10.
25. Dodson PM, Haynes J, Starczynski J, et al. The platelet glycoprotein
Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal
vein occlusion. Eye (Lond). 2003;17:772-7.
26. Wu G, Xi Y, Yao L, et al. Genetic polymorphism of ITGA2 C807T can
increase the risk of ischemic stroke. Int J Neurosci. 2014;124:841-51.
27. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart
disease and stroke statistics–2010 update: a report from the American
Heart Association. Circulation. 2010;121:948-54.